BOTANIX PHARMACEUTICALS LTD — Board/Management Information 2021

Sep 23, 2021

==> picture [114 x 50] intentionally omitted <==

24 September 2021

Botanix Expands Management Team

Key highlights

• Botanix expands management team with the appointment of a new Senior Vice President of Pharmaceutical Development – Dr Jack Hoblitzell

• Dr Hoblitzell adds significant experience leading world class technical operations to deliver new product launches and excellence in manufacturing and supply chain management

• Additional appointment to the management team further supports plans for pipeline development and to accelerate the development and scale-up of commercial capabilities

Philadelphia PA and Perth Australia, 24 September 2021 : Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), is pleased to announce the expansion of its management team with the appointment of Dr Jack Hoblitzell as Senior Vice President of Pharmaceutical Development.

Vince Ippolito, President and Executive Chairman, commented: “We are pleased to welcome Jack to the Botanix team. His depth of experience and success in leading successful new product launches and regulatory submissions will be invaluable as we continue to focus on our clinical programs as they move into last stage studies and commercial manufacturing, as well as our increasing work with the Permetrex platform.”

Dr Hoblitzell was most recently SVP, Technical Operations at Assertio Therapeutics Inc. leading all aspects of manufacturing and supply chain, including quality, regulatory and pharmacovigilance operations. Serving on the executive team, Dr Hoblitzell oversaw the integration of Assertio Therapeutics and Zyla Life Sciences in 2020, where he was previously VP Technical Operations.

Dr Hoblitzell has over 30 years of extensive experience in leading world-class technical operations to manufacture and deliver branded, specialty and generic pharmaceuticals, previously holding senior leadership roles in the US with companies including Pfizer, King Pharmaceuticals, Ivax Pharmaceuticals and Teva Pharmaceuticals. This includes expertise in areas such as M&A due diligence, manufacturing technology transfer and integration in addition to manufacturing for pivotal studies and regulatory submission documentation. Dr Hoblitzell has a depth of experience in supply chain management and operational excellence delivery having successfully led sales and operations planning and distribution for both marketed and new products, including implementation and oversight of technical contract manufacturing and packaging.

Dr Hoblitzell is Registered Pharmacist and member of the American Association of Pharmaceutical Scientists (AAPS), and International Society of Pharmaceutical Engineers (IPSE). He holds his PhD in Pharmaceutics and BS Pharmacy from the University of Rhode Island.

==> picture [113 x 50] intentionally omitted <==

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology focused company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two separate development platforms - dermatology and antimicrobial products - both of which currently leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol or CBD. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities.

The Company is developing a pipeline of product candidates with recent positive data from its BTX 1801 Phase 2a antimicrobial study and its Phase 1b rosacea clinical study is currently enrolling patients. Following a successful meeting with the FDA, the Company has also confirmed a drug development plan for the BTX 1503 acne Phase 3 program to support registration. In addition, Botanix plans to advance its BTX 1204A atop dermatitis program to a proof of concept canine study in Q3 CY2021 following encouraging early data from a recent pilot study. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries	Investor enquiries	Media enquiries
Corporate Communications	Joel Seah	Haley Chartres
Botanix Pharmaceuticals	Vesparum Capital	H^CK
P: +61 8 6555 2945	P: +61 3 8582 4800	P: +61 423 139 163
investors@botanixpharma.com	botanixpharma@vesparum.com	haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” ”potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for is product candidates. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some

==> picture [113 x 50] intentionally omitted <==

point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.